Pfizer IncChange company Symbol lookupSelect an option...PFE Pfizer IncSCBH Seacoast Commerce Banc HoldingsPHX Panhandle Oil and Gas IncBTU Peabody Energy CorpCLNY Colony Capital IncBAC Bank of America CorpUSAK USA Truck IncBABA Alibaba Group Holding LtdCTL Centurylink IncCSCO Cisco Systems IncGo
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
|
|
|
|
|
Values displayed are in millions.
| Q4 2018 12/31/18 | Q1 2019 03/31/19 | Q2 2019 06/30/19 | Q3 2019 09/29/19 | |
|---|---|---|---|---|
| Net Income | 11,188 | 3,889 | 8,945 | 16,628 |
| Depreciation/Depletion | 6,384 | 1,545 | 3,073 | 4,626 |
| Deferred Taxes | (2,205) | (60) | (160) | 2,067 |
| Discontinued Operations | (1) | -- | -- | -- |
| Extraordinary Item | (596) | (131) | (285) | (319) |
| Unusual Items | 3,398 | 155 | 178 | (8,009) |
| Other Non-Cash Items | (319) | (51) | (78) | (174) |
| Non-Cash Items | 2,482 | (27) | (185) | (8,502) |
| Cash Taxes Pd, Supplemental | 3,655 | 235 | 2,136 | 2,636 |
| Cash Interest Pd, Suppl | 1,311 | 385 | 809 | 1,246 |
| Accounts Receivable | (644) | -- | -- | -- |
| Inventories | (717) | -- | -- | -- |
| Other Assets | (16) | -- | -- | -- |
| Accounts Payable | 431 | -- | -- | -- |
| Accrued Expenses | (1,095) | (151) | (313) | (429) |
| Changes in Working Capital | (2,022) | (3,650) | (7,363) | (6,001) |
| Total Cash from Operations | 15,827 | 1,697 | 4,310 | 8,818 |
Values displayed are in millions.
| Q4 2018 12/31/18 | Q1 2019 03/31/19 | Q2 2019 06/30/19 | Q3 2019 09/29/19 | |
|---|---|---|---|---|
| Purchase of Fixed Assets | (2,042) | (460) | (939) | (1,504) |
| Purchase/Acq of Intangibles | (154) | (158) | (267) | (364) |
| Capital Expenditures | (2,196) | (618) | (1,206) | (1,868) |
| Acquisition of Business | 0 | -- | -- | (10,861) |
| Sale/Maturity of Investment | 23,825 | 3,645 | 6,143 | 7,882 |
| Investment, Net | (3,917) | 5,941 | 4,717 | 8,307 |
| Purchase of Investments | (13,474) | (1,486) | (4,186) | (4,717) |
| Other Investing Cash Flow | 287 | 68 | 180 | 145 |
| OtherInvestCashFlowItms,Tot | 6,721 | 8,168 | 6,854 | 756 |
| Total Cash from Investing | 4,525 | 7,550 | 5,648 | (1,112) |
Values displayed are in millions.
| Q4 2018 12/31/18 | Q1 2019 03/31/19 | Q2 2019 06/30/19 | Q3 2019 09/29/19 | |
|---|---|---|---|---|
| Financing Cash Flow Items | (589) | (496) | (541) | (666) |
| Total Cash Dividends Paid | (7,978) | (2,045) | (4,047) | (6,051) |
| Common Stock, Net | (12,198) | (8,865) | (8,865) | (8,865) |
| Options Exercised | 1,259 | 126 | 248 | 303 |
| Iss (Retirmnt) of Stock,Net | (10,939) | (8,739) | (8,617) | (8,562) |
| Short Term Debt Issued | 3,711 | 609 | 3,956 | 11,582 |
| Short Term Debt Reduction | (4,437) | (1,766) | (2,375) | (4,088) |
| Short Term Debt, Net | (2,343) | 875 | 4,300 | 10,098 |
| Long Term Debt Issued | 4,974 | 4,942 | 4,942 | 4,942 |
| Long Term Debt Reduction | (3,566) | (3,004) | (5,355) | (5,806) |
| Long Term Debt, Net | 1,408 | 1,938 | (413) | (864) |
| Iss (Retirmnt) of Debt, Net | (935) | 2,813 | 3,887 | 9,234 |
| Total Cash From Financing | (20,441) | (8,467) | (9,318) | (6,045) |
Values displayed are in millions.
| Q4 2018 12/31/18 | Q1 2019 03/31/19 | Q2 2019 06/30/19 | Q3 2019 09/29/19 | |
|---|---|---|---|---|
| Foreign Exchange Effects | (116) | 12 | (28) | (41) |
| Net Change in Cash | (205) | 792 | 612 | 1,620 |
| NetCash-BeginBal/RsvdforFutUse | 1,431 | 1,225 | 1,225 | 1,225 |
| NetCash-EndBal/RsrvforFutUse | 1,225 | 2,018 | 1,837 | 2,846 |
| Depreciation, Supplemental | 6,384 | 1,545 | 3,073 | 4,626 |
Copyright © 2020. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.